At the 8th Vaccine and ISV Conference in Philadelphia on 27−28 October 2014, Novavax Inc. reported the development in a "few weeks" of a glycoprotein (GP) nanoparticle Ebola virus (EBOV GP) vaccine using their proprietary recombinant technology.

Feb 12, 2015 · The Phase 1 clinical trial initiation is supported by significant immunogenicity and efficacy data demonstrating that the Ebola GP Vaccine is the first subunit Ebola GP-based vaccine to provide protection in non-human primates.

Jul 23, 2020 · Ebola virus GP vaccine with Matrix-M adjuvant is well tolerated and elicits a robust and persistent immune response. These data suggest that further development of this candidate vaccine for prevention of EBOV disease is warranted.

This vaccine includes Novavax, Inc.’s proprietary adjuvant Matrix-M, which has been shown to improve EBOV protective efficacy in mice 113 and NHPs. 114 Early safety and immunogenicity results from this trial are encouraging, as all vaccinees receiving the adjuvanted vaccine seroconverted. 114 The NHP and clinical study data suggest a possible ...

Jul 21, 2015 · The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35.

Following the large Ebola outbreaks that occurred in several West African countries between 2013 and 2016, Novavax developed a recombinant Ebola virus (EBOV) GP nanoparticle vaccine formulated with Matrix-M. 27,85 In BALB/c mice, EBOV GP co-administered with Matrix-M was significantly more immunogenic than GP co-administered with aluminum ...

Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health.

Apr 7, 2016 · Matrix-M adjuvanted vaccine induced a rapid onset of specific IgG and neutralizing antibodies, increased frequency of multifunctional CD4+ and CD8 (+) T cells, specific TFH cells, germinal center B cells, and persistence of EBOV GP-specific plasma B cells in the bone marrow.

Jul 22, 2015 · Novavax has announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™.

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.